z
Sharma, N.L., M.D., D.C.H. (Lond.), F.R.S.T.M.& H. (Eng.), D.T.M., D.P.H. (Cal.), Professor and Head of the Department of Pediatrics Lahori, U.C., M.D., D.C.H., Research Scholar and Mehta, S.K., B.Sc., M.B.,B.S., D.C.H., Research Scholar, King George’s Medical College, Lucknow, U.P., India.
Liver diseases continue to be one of the major causes of morbidity and mortality in children. The treatment of most of the diseases remains non-specific, expensive and unrewarding. With this background the effectiveness of Liv.52 was evaluated in 155 cases of different hepatic disorders in childhood.
MATERIAL AND METHODS
The present study was carried out at the Department of Pediatrics, K.G. Medical College, Lucknow. 155 patients with various liver disorders were personally examined and observed and the data were collected on a previously prepared proforma. The clinical and laboratory observations and progress were noted from time to time.
The diagnosis of all these cases was made on the basis of clinical features, routine investigations of blood, urine, stool and other special investigations like serum biochemistry, liver function tests (L.F.T.), X-rays and liver biopsy etc. In spite of all attempts it was possible to carry out liver biopsy in 16 cases and in only one case of infective hepatitis. Most of the patients were unwilling to submit to this procedure after improvement and others were too low to allow this procedure.
Liv.52 was administered in the following dosage:
Below 3 years 10-15 drops q.i.d. 3-5 years 20 drops q.i.d. Above 5 years 2 tablets t.i.d.
GROUP I
Viral Hepatitis — 58 cases
In this group we included cases of neonatal hepatitis, infective hepatitis, and serum hepatitis. In four cases the diagnosis of neonatal hepatitis was confirmed on clinical examination and the laboratory findings of initial normal coloured stools becoming acholic after several weeks, persistent conjugated hyperbilirubinaemia, positive tests for urobilinogen in urine and stools and the findings of bile salts and pigments in the urine and high levels of blood bilirubin. Four cases were included in the present study as they satisfied these criteria. Out of the 54 cases of viral hepatitis, two cases gave a history of blood transfusion and the onset was insidious hence were labelled as serum hepatitis cases. Fifty two cases were probably of infective hepatitis although a definite history of contact was present in 32 cases. In these cases the onset was with fever, gastro intestinal symptoms like anorexia, nausea, vomiting, upper abdominal distress and pain, constipation or diarrhoea following contact with a patient of viral hepatitis. On examination, there was jaundice with enlarged, soft and tender liver and liver function tests suggestive of acute viral hepatitis.
The cases were divided into two subgroups.
Sub-group A — With Liv.52:
Viral hepatitis treated with Liv.52 plus minerals and vitamins 32 cases
Sub-group B — Without Liv.52:
Viral hepatitis treated only with minerals and vitamins 26 cases
The cases were followed up regularly. Signs and symptoms and their progress were observed and the laboratory findings were noted in each group.
OBSERVATIONS AND RESULTS
In Group I — Viral Hepatitis—58 cases
The majority of cases were between one month to 14 years: 36 were males and 22 were females. The drug was found equally effective in all the categories of cases and the response was encouraging in all of them (Table II). There was quicker symptomatic improvement in the form of increase in appetite, general well-being and gain in weight. Fever responded earlier, jaundice and tenderness of the liver disappeared earlier and there was quicker improvement in gastrointestinal symptoms. There was substantial improvement in liver function tests in all cases (Tables III and IV).
Refference: http://www.himalayahealthcare.com/pdf_files/liv217.pdf
Studies on Liv.52 in hepatic disorders
Sharma, N.L., M.D., D.C.H. (Lond.), F.R.S.T.M.& H. (Eng.), D.T.M., D.P.H. (Cal.), Professor and Head of the Department of Pediatrics Lahori, U.C., M.D., D.C.H., Research Scholar and Mehta, S.K., B.Sc., M.B.,B.S., D.C.H., Research Scholar, King George’s Medical College, Lucknow, U.P., India.
Liver diseases continue to be one of the major causes of morbidity and mortality in children. The treatment of most of the diseases remains non-specific, expensive and unrewarding. With this background the effectiveness of Liv.52 was evaluated in 155 cases of different hepatic disorders in childhood.
MATERIAL AND METHODS
The present study was carried out at the Department of Pediatrics, K.G. Medical College, Lucknow. 155 patients with various liver disorders were personally examined and observed and the data were collected on a previously prepared proforma. The clinical and laboratory observations and progress were noted from time to time.
The diagnosis of all these cases was made on the basis of clinical features, routine investigations of blood, urine, stool and other special investigations like serum biochemistry, liver function tests (L.F.T.), X-rays and liver biopsy etc. In spite of all attempts it was possible to carry out liver biopsy in 16 cases and in only one case of infective hepatitis. Most of the patients were unwilling to submit to this procedure after improvement and others were too low to allow this procedure.
Liv.52 was administered in the following dosage:
Below 3 years 10-15 drops q.i.d. 3-5 years 20 drops q.i.d. Above 5 years 2 tablets t.i.d.
GROUP I
Viral Hepatitis — 58 cases
In this group we included cases of neonatal hepatitis, infective hepatitis, and serum hepatitis. In four cases the diagnosis of neonatal hepatitis was confirmed on clinical examination and the laboratory findings of initial normal coloured stools becoming acholic after several weeks, persistent conjugated hyperbilirubinaemia, positive tests for urobilinogen in urine and stools and the findings of bile salts and pigments in the urine and high levels of blood bilirubin. Four cases were included in the present study as they satisfied these criteria. Out of the 54 cases of viral hepatitis, two cases gave a history of blood transfusion and the onset was insidious hence were labelled as serum hepatitis cases. Fifty two cases were probably of infective hepatitis although a definite history of contact was present in 32 cases. In these cases the onset was with fever, gastro intestinal symptoms like anorexia, nausea, vomiting, upper abdominal distress and pain, constipation or diarrhoea following contact with a patient of viral hepatitis. On examination, there was jaundice with enlarged, soft and tender liver and liver function tests suggestive of acute viral hepatitis.
Table I: Symptoms and signs |
|||||||||||||||||||
|
Total No. of Viral Hepatitis cases = 58 |
||||||||||||||||||
Number with positive signs & symptoms |
% |
||||||||||||||||||
1. |
Fever |
40 |
68.96 |
||||||||||||||||
2. |
Anorexia |
46 |
79.31 |
||||||||||||||||
3. |
Vomiting |
24 |
41.38 |
||||||||||||||||
4. |
Diarrhoea |
2 |
3.45 |
||||||||||||||||
5. |
Constipation |
8 |
13.79 |
||||||||||||||||
6. |
Abdominal distension |
6 |
10.34 |
||||||||||||||||
7. |
Jaundice |
54 |
93.10 |
||||||||||||||||
8. |
Irritability |
2 |
3.45 |
||||||||||||||||
9. |
Oedema |
Nil |
— |
||||||||||||||||
10. |
Underweight |
8 |
13.79 |
||||||||||||||||
11. |
Anaemia |
6 |
10.34 |
||||||||||||||||
12. |
Lymphadenopathy |
5 |
8.62 |
||||||||||||||||
13. |
Liver Size:– |
Upto 3 cm |
48 |
82.76 |
|||||||||||||||
3-5 cm |
10 |
17.24 |
|||||||||||||||||
14. |
Spleen:– |
Upto 3 cm |
10 |
17.24 |
|||||||||||||||
3-5 cm |
Nil |
— |
|||||||||||||||||
The cases were divided into two subgroups.
Sub-group A — With Liv.52:
Viral hepatitis treated with Liv.52 plus minerals and vitamins 32 cases
Sub-group B — Without Liv.52:
Viral hepatitis treated only with minerals and vitamins 26 cases
The cases were followed up regularly. Signs and symptoms and their progress were observed and the laboratory findings were noted in each group.
OBSERVATIONS AND RESULTS
In Group I — Viral Hepatitis—58 cases
The majority of cases were between one month to 14 years: 36 were males and 22 were females. The drug was found equally effective in all the categories of cases and the response was encouraging in all of them (Table II). There was quicker symptomatic improvement in the form of increase in appetite, general well-being and gain in weight. Fever responded earlier, jaundice and tenderness of the liver disappeared earlier and there was quicker improvement in gastrointestinal symptoms. There was substantial improvement in liver function tests in all cases (Tables III and IV).
Refference: http://www.himalayahealthcare.com/pdf_files/liv217.pdf
Copyrights © 2009 healthyliver.co.uk